Imagion Biosystems 2020 Full Year Results
2020 Highlights: MagSense® HER2 breast cancer Phase I study initiated Collaboration with Siemens Healthineers explores MagSense® nanoparticles using MRI Total…
Quarterly Activity Report for 31 December 2020 — Appendix 4C
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 December 2020 (Q4…
Imagion Biosystems December 2020 Investor Newsletter
Imagion Biosystems is pleased to provide its investors with its December 2020 Investor Newsletter. The newsletter details recent new company developments and…
First In-human Study Update: Study Open for Enrolment
Imagion Biosystems is pleased to announce that Monash Health has been established as the first clinical site and is ready to commence enrolment of patients for…
Proposed Issue of Securities — Appendix 3B
Imagion Biosystems has announced a Proposed Issue of Securities. Read the announcement.
IBX Raises $6M in Placement
Highlights: $6M raised in a heavily oversubscribed placement at 8.5c per share – a 6% discount to the 30-day VWAP. Placement strongly supported by…
Trading Halt
The securities of Imagion Biosystems will be placed in trading halt the request of IBX, pending it releasing an announcement. Read the ASX announcement and the…
Statement Pursuant to Listing Rule 4.7C.3
Imagion Biosystems advises that in accordance with Listing Rule 4.7C.3, and as noted in the Item 6 of the Appendix 4C Cashflow Statement lodged by the Company…
New Imaging Technology for Early Detection
Early detection is critical to improving cancer survival rates. Too often, the limitations of today's medical imaging technologies result in cancer being…
Appendix C and Quarterly Activity Report
Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 30 September 2020 (Q3…